Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Until now, no randomized, placebo-controlled, long-term trial has tested this drug in individuals with chronic kidney disease who are not receiving dialysis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chonchol, M. et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am. J. Kidney Dis. 53, 197–207 (2009).
Block, G. A. et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15, 2208–2218 (2004).
Kalantar-Zadeh, K. et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 70, 771–780 (2006).
Kestenbaum, B. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 16, 520–528 (2005).
Coyne, D. et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 47, 263–276 (2006).
Gutierrez, O. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16, 2205–2215 (2005).
Serra, A. L., Wuhrmann, C. & Wüthrich, R. P. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am. J. Kidney Dis. 52, 1151–1157 (2008).
Naves-Díaz, M. et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 74, 1070–1078 (2008).
Agarwal, R. et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 68, 2823–2828 (2005).
Alam, M. U. et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc. Res. 81, 260–268 (2009).
Meola, M., Petrucci, I. & Barsotti, G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol. Dial. Transplant. 24, 982–989 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. B. Cannata-Andía has received grant/research support and speakers' bureaux honoraria from Amgen, and grant/research support from Fresenius. J. L. Fernández-Martín declared no competing interests.
Rights and permissions
About this article
Cite this article
Cannata-Andía, J., Fernández-Martín, J. Should cinacalcet be used in patients who are not on dialysis?. Nat Rev Nephrol 5, 307–308 (2009). https://doi.org/10.1038/nrneph.2009.54
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.54
This article is cited by
-
New therapies: calcimimetics, phosphate binders and vitamin D receptor activators
Pediatric Nephrology (2010)
